Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration

Yao, Wei; Zhang, Jichun; Dong, Chao; Zhuang, Cun; Hirota, Susumu; Inanaga, Kazutoyo; Hashimoto, Kenji

doi:10.1016/j.pbb.2015.06.012

Cited by 38 publications

(41 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The behavior results from the activation of proinflammatory cytokine signaling in the brain, in response to peripheral LPS injection, and the ensuing depression-like behavior peaks 24 h post-LPS injection [1,6]. In this study, we found that SFN showed antiinflammatory and antidepressant effects in LPS model of depression, consistent with previous reports using the current antidepressants [11][12][13]48]. SFN is considered to have a low toxicity [24,50,51], and SFN readily crosses the bloodbrain barrier (BBB) of mouse after ip administration [52].…”

Section: Discussionsupporting

confidence: 90%

“…In vehicle-treated mice, serum levels of TNF-α were very low (Fig. 1B), consistent with the previous report [12,13,48]. Serum levels of TNF-α were significantly increased after a single administration of LPS (0.5 mg/kg) (Fig.…”

Section: Effects Of Sfn On Serum Levels Of Tnf-α Il-10 and Mac1 Immusupporting

confidence: 91%

“…LPS and SFN were administered intraperitoneally (ip) into mice. The doses of LPS (0.5 mg/kg) and SFN were selected by previous reports [10][11][12][13][29][30][31]]. …”

Section: Drug Administrationmentioning

confidence: 99%

“…When the bacterial endotoxin lipopolysaccharide (LPS) is administered to rodents, depression-like behaviors are observed 24 h after inflammation [1,6,10]. The current antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), are able to prevent depression-like behavior and alterations in serum proinflammatory cytokines, such as TNF-α, induced by LPS administration [10][11][12][13]. These all findings suggest that inflammation is associated with depressive symptoms and that antiinflammatory drugs could ameliorate depressive symptoms in patients with depression.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation

Zhang

Yao

Dong

et al. 2017

The Journal of Nutritional Biochemistry

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Section: Effects Of Sfn On Serum Levels Of Tnf-α Il-10 and Mac1 Immusupporting

confidence: 91%

“…LPS and SFN were administered intraperitoneally (ip) into mice. The doses of LPS (0.5 mg/kg) and SFN were selected by previous reports [10][11][12][13][29][30][31]]. …”

Section: Drug Administrationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation

Zhang

Yao

Dong

et al. 2017

The Journal of Nutritional Biochemistry

Self Cite

View full text Add to dashboard Cite

“…Peripheral administration of the bacterial endotoxin lipopolysaccharide (LPS) induces depression-like behavior in rodents after the induction of inflammation (Dantzer et al 2008; O’Connor et al 2009; Remus and Dantzer 2016; Zhang et al 2016). LPS-induced depression-like behavior can be blocked by pretreatment with antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (Dong et al 2016; Ma et al 2014; Ohgi et al 2013; Yao et al 2015). These findings suggest that inflammation might be associated with depressive symptoms.…”

Section: Introductionmentioning

confidence: 99%

Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation

Ren

Yang

et al. 2016

Psychopharmacology

Self Cite

View full text Add to dashboard Cite

RationaleAddition of low doses of atypical antipsychotic drugs with selective serotonin reuptake inhibitors (SSRIs) could promote a rapid antidepressant effect in treatment-resistant patients with major depression. Brexpiprazole, a new atypical antipsychotic drug, has been used as adjunctive therapy for the treatment of major depression.ObjectivesThe present study was undertaken to examine whether brexpiprazole could augment antidepressant effects of the SSRI fluoxetine in an inflammation model of depression.MethodsWe examined the effects of fluoxetine (10 mg/kg), brexpiprazole (0.1 mg/kg), or the combination of the two drugs on depression-like behavior, alterations in the brain-derived neurotrophic factor (BDNF) - TrkB signaling, and dendritic spine density in selected brain regions after administration of lipopolysaccharide (LPS) (0.5 mg/kg).ResultsCombination of brexpiprazole and fluoxetine promoted a rapid antidepressant effect in inflammation model although brexpipazole or fluoxetine alone did not show antidepressant effect. Furthermore, the combination significantly improved LPS-induced alterations in the BDNF - TrkB signaling and dendritic spine density in the prefrontal cortex, CA3 and dentate gyrus, and nucleus accumbens.ConclusionsThese results suggest that add-on of brexpiprazole to fluoxetine can produce a rapid antidepressant effect in the LPS inflammation model of depression, indicating that adjunctive therapy of brexpiprazole to SSRIs could produce a rapid antidepressant effect in depressed patients with inflammation.

show abstract

Gene–disease association study of tumor necrosis factor‐α G‐308A gene polymorphism with risk of major depressive disorder: A systematic review and meta‐analysis

Wang

Zhang

et al. 2020

Brain and Behavior

View full text Add to dashboard Cite

MDD is a common and debilitating mood disease in the world characterized by pervasive and persistent low mood. It is accompanied by psychological and physiological symptoms, such as lack of motivation, changes in appetite, inability to feel pleasure, cognitive difficulties, and retraction from social interaction (Chan, Cathomas, & Russo, 2019). The proportion of the global population living with MDD is estimated to be 4.4%, representing the primary cause of disability worldwide (Zhao, Li, Tian, Zhu, & Zhao, 2019). Although extensive studies have been investigated over the last few decades, the etiology of depression is still not completely explained, which

show abstract

Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration

Cited by 38 publications

References 39 publications

Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation

Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation

Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation

Gene–disease association study of tumor necrosis factor‐α G‐308A gene polymorphism with risk of major depressive disorder: A systematic review and meta‐analysis

Contact Info

Product

Resources

About